

Edgar Filing: RESPIRONICS INC - Form 10-Q

RESPIRONICS INC  
Form 10-Q  
May 15, 2002

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D. C. 20549

FORM 10-Q

(Mark One)

Quarterly Report pursuant to section 13 or 15(d) of the Securities  
Exchange Act of 1934 for the quarterly period ended March 31, 2002

or

Transition Report pursuant to section 13 or 15(d) of the Securities  
Exchange Act of 1934 for the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission File No. 000-16723

RESPIRONICS, INC.

(Exact name of registrant as specified in its charter)

Delaware 25-1304989  
(State or other jurisdiction of (I.R.S. Employer Identification Number)  
incorporation or organization)

1010 Murry Ridge Lane  
Murrysville, Pennsylvania 15668-8525  
(Address of principal executive offices) (Zip Code)

(Registrant's Telephone Number, including area code) 724-387-5200

Indicate by check mark whether the registrant (1) has filed all reports required  
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during  
the preceding 12 months (or for such shorter period that the registrant was  
required to file such reports), and (2) has been subject to such filing  
requirements for the past 90 days. Yes  No

As of April 30, 2002, there were 34,224,290 shares of Common Stock of the  
registrant outstanding, of which 3,592,942 were held in treasury.

INDEX

RESPIRONICS, INC.

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited).

Independent Accountants' Review Report

Consolidated balance sheets -- March 31, 2002 and June 30, 2001.

## Edgar Filing: RESPIRONICS INC - Form 10-Q

Consolidated statements of operations -- Three months and nine months ended March 31, 2002 and 2001.

Consolidated statements of cash flows -- Nine months ended March 31, 2002 and 2001.

Notes to consolidated financial statements - March 31, 2002.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

### PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

Item 2. Changes in Securities.

Item 3. Defaults Upon Senior Securities.

Item 4. Submission of Matters to a Vote of Security Holders.

Item 5. Other Information.

Item 6. Exhibits and Reports on Form 8-K.

### SIGNATURES

#### Independent Accountants' Review Report

Board of Directors  
Respironics, Inc. and Subsidiaries

We have reviewed the accompanying condensed consolidated balance sheet of Respironics, Inc. and Subsidiaries as of March 31, 2002, and the related condensed consolidated statements of operations for the three-month and nine-month periods ended March 31, 2002 and 2001, and the condensed consolidated statements of cash flows for the nine-month periods ended March 31, 2002 and 2001. These financial statements are the responsibility of the Company's management.

We conducted our reviews in accordance with standards established by the American Institute of Certified Public Accountants. A review of interim financial information consists principally of applying analytical procedures to financial data, and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with auditing standards generally accepted in the United States, which will be performed for the full year with the objective of expressing an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should be made to the accompanying condensed consolidated financial statements referred to above for them to be in conformity with accounting principles generally accepted in the United States.

We have previously audited, in accordance with auditing standards generally accepted in the United States, the consolidated balance sheet of Respironics,

## Edgar Filing: RESPIRONICS INC - Form 10-Q

Inc. and Subsidiaries as of June 30, 2001, and the related consolidated statements of operations, shareholders' equity, and cash flows for the year then ended not presented herein and in our report dated July 24, 2001, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of June 30, 2001, is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.

/s/ Ernst & Young LLP

Pittsburgh, Pennsylvania  
April 24, 2002

### CONSOLIDATED BALANCE SHEETS (UNAUDITED)

#### RESPIRONICS, INC. AND SUBSIDIARIES

	March 31 2002	June 30 2001
	-----	-----
ASSETS		
CURRENT ASSETS		
Cash and short-term investments	\$ 48,826,544	\$ 27,320,910
Trade accounts receivable, less allowance for doubtful accounts of \$17,635,000 and \$16,457,000	105,731,285	98,078,344
Inventories	66,916,080	73,417,896
Prepaid expenses and other	10,741,252	10,937,110
Deferred income tax benefits	14,855,307	14,855,307
	-----	-----
TOTAL CURRENT ASSETS	247,070,468	224,609,567
PROPERTY, PLANT AND EQUIPMENT		
Land	2,506,052	2,506,052
Building	8,574,421	8,509,596
Machinery and equipment	96,575,852	84,559,172
Furniture, office and computer equipment	65,797,728	56,011,341
Leasehold improvements	5,759,615	5,286,891
	-----	-----
	179,213,668	156,873,052
Less allowances for depreciation and amortization	107,002,956	87,725,808
	-----	-----
	72,210,712	69,147,244
OTHER ASSETS	16,337,589	14,334,938
GOODWILL	57,696,234	59,856,714
	-----	-----
	\$ 393,315,003	\$ 367,948,463
	=====	=====

See notes to consolidated financial statements.

Edgar Filing: RESPIRONICS INC - Form 10-Q

	March 31 2002	June 30 2001
-----		
LIABILITIES AND SHAREHOLDERS' EQUITY		
CURRENT LIABILITIES		
Accounts payable	\$ 31,291,385	\$ 28,964,129
Accrued expenses and other	23,973,030	19,662,491
Current portion of long-term obligations	661,923	3,998,317
	-----	-----
TOTAL CURRENT LIABILITIES	55,926,338	52,624,937
LONG-TERM OBLIGATIONS	69,376,520	80,055,378
SHAREHOLDERS' EQUITY		
Common Stock, \$.01 par value; authorized 100,000,000 shares; issued and outstanding 34,189,125 shares at March 31, 2002 and 34,013,785 shares at June 30, 2001	341,891	340,138
Additional capital	124,577,819	121,720,289
Accumulated other comprehensive loss	(4,096,741)	(4,237,433)
Retained earnings	189,408,996	160,033,521
Treasury stock	(42,219,820)	(42,588,367)
	-----	-----
TOTAL SHAREHOLDERS' EQUITY	268,012,145	235,268,148
	-----	-----
	\$ 393,315,003	\$ 367,948,463
	=====	=====

See notes to consolidated financial statements.

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

RESPIRONICS, INC. AND SUBSIDIARIES

	Three months ended	
	March 31 2002	March 31 2001
-----		
Net sales	\$ 126,708,403	\$ 110,207,939
Cost of goods sold	67,144,406	58,695,623
Cost of goods sold - restructuring charges	0	724,990
	-----	-----
GROSS MARGIN	59,563,997	50,787,326
General and administrative expenses	15,397,699	13,221,926
Sales, marketing and commission expenses	21,118,867	18,639,614
Research and development expenses	3,904,476	3,744,747
Restructuring credit	0	(1,908,581)
Interest expense	676,246	1,839,631
Other income	(238,828)	(272,030)
	-----	-----

Edgar Filing: RESPIRONICS INC - Form 10-Q

	40,858,460	35,265,307
	-----	-----
INCOME BEFORE INCOME TAXES	18,705,537	15,522,019
Income taxes	7,389,435	6,208,807
	-----	-----
NET INCOME	\$ 11,316,102	\$ 9,313,212
	=====	=====
Basic earnings per share	\$ 0.37	\$ 0.31
	=====	=====
Basic shares outstanding	30,582,388	30,228,829
Diluted earnings per share	\$ 0.36	\$ 0.30
	=====	=====
Diluted shares outstanding	31,441,712	31,169,860

See notes to consolidated financial statements.

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

RESPIRONICS, INC. AND SUBSIDIARIES

	Nine Months Ended March 31 2002	2001
	-----	-----
OPERATING ACTIVITIES		
Net income	\$ 29,375,475	\$ 23,613,819
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	24,818,539	21,386,453
Asset sales and write-offs	0	(877,000)
Changes in operating assets and liabilities:		
Increase in accounts receivable	(7,652,941)	(5,519,518)
Decrease (increase) in inventories	6,501,816	(8,449,468)
Change in other operating assets and liabilities	2,797,652	(4,013,339)
	-----	-----
NET CASH PROVIDED BY OPERATING ACTIVITIES	55,840,541	26,140,947
INVESTING ACTIVITIES		
Purchase of property, plant and equipment	(22,940,974)	(22,650,374)
Additional purchase price for acquired business	(606,511)	(787,580)
	-----	-----
NET CASH USED BY INVESTING ACTIVITIES	(23,547,485)	(23,437,954)
FINANCING ACTIVITIES		
Net decrease in borrowings	(14,015,252)	(15,217,724)
Issuance of common stock	2,859,283	6,573,497
Use of treasury stock, net	368,547	761,556
	-----	-----

Edgar Filing: RESPIRONICS INC - Form 10-Q

NET CASH USED BY FINANCING ACTIVITIES	(10,787,422)	(7,882,671)
	-----	-----
INCREASE (DECREASE) IN CASH AND SHORT-TERM INVESTMENTS	21,505,634	(5,179,678)
Cash and short-term investments at beginning of period	27,320,910	19,594,484
	-----	-----
CASH AND SHORT-TERM INVESTMENTS AT END OF PERIOD	\$ 48,826,544	\$ 14,414,806
	=====	=====

See notes to consolidated financial statements.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

RESPIRONICS, INC. AND SUBSIDIARIES

March 31, 2002

NOTE A -- BASIS OF PRESENTATION

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months and nine months ended March 31, 2002 are not necessarily indicative of the results that may be expected for the year ended June 30, 2002. For further information, refer to the consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended June 30, 2001.

NOTE B -- INVENTORIES

The composition of inventory is as follows:

	March 31 2002	June 30 2001
	-----	-----
Raw materials	\$15,198,000	\$20,738,000
Work-in-process	4,026,000	5,961,000
Finished goods	47,692,000	46,719,000
	-----	-----
	\$66,916,000	\$73,418,000
	=====	=====

NOTE C -- CONTINGENCIES

As previously disclosed, the Company is party to actions filed in a Federal District Court in January 1995 and June 1996 in which a competitor alleges that the Company's manufacture and sale in the United States of certain products infringes four of the competitor's patents. In its response to these actions, the Company has denied the allegations and has separately sought judgment that the claims under the patents are invalid or unenforceable and that the Company does not infringe upon the patents. The January 1995 and June 1996 actions have

## Edgar Filing: RESPIRONICS INC - Form 10-Q

been

consolidated. The Court has granted the Company's various motions for summary judgment and held that the Company does not infringe any of the competitor's four patents at issue. The competitor may seek an appeal of those decisions. In any event, the Company intends to continue to pursue its claims that the competitor's patents are invalid or unenforceable.

The Company is, as a normal part of its business operations, a party to other legal proceedings in addition to those previously described by filings of the Company. Legal counsel has been retained for each proceeding and none of these proceedings is expected to have a material adverse impact on the Company's results of operations or financial condition.

### NOTE D -- RESTRUCTURING CHARGES

In July 1999, the Company announced a major restructuring of its U.S. operations that included facility closings and downsizings, a management realignment, and a workforce reduction associated with those changes. The workforce reduction involved approximately 200 employees in areas of executive management, manufacturing, engineering, sales and marketing, administration, and service. The following table summarizes these restructuring charges and corresponding expenditures.

### RECONCILIATION OF RESTRUCTURING RESERVES

	Employee Severance Costs	Asset Write-Downs	Lease Bu & Other Expen
	-----	-----	-----
Balance at July 1, 1999	\$ -	\$ -	\$ -
Restructuring charges (net)	6,300,000	8,900,000	14,000,000
Cash expenditures	(3,100,000)	-	(12,900,000)
Noncash expenditures	-	(1,700,000)	-
	-----	-----	-----
Balance at June 30, 2000	3,200,000	7,200,000	1,100,000
	-----	-----	-----
Restructuring charges (net)	(200,000)	1,000,000	-
Cash expenditures	(1,500,000)	-	(900,000)
Noncash expenditures	-	(2,500,000)	-
	-----	-----	-----
Balance at June 30, 2001	1,500,000	5,700,000	200,000
	-----	-----	-----
Restructuring charges (net)	-	-	-
Cash expenditures	(400,000)	-	-
Noncash expenditures	-	(400,000)	-
	-----	-----	-----
Balance at September 30, 2001	1,100,000	5,300,000	200,000
	-----	-----	-----
Restructuring charges (net)	-	-	-
Cash expenditures	(400,000)	-	-
Noncash expenditures	-	-	-
	-----	-----	-----
Balance at December 31, 2001	700,000	5,300,000	200,000
	-----	-----	-----

Edgar Filing: RESPIRONICS INC - Form 10-Q

Restructuring charges (net)	-	-	
Cash expenditures	(300,000)	-	(10
Noncash expenditures	-	(100,000)	
	-----	-----	-----
Balance at March 31, 2002	\$ 400,000	\$ 5,200,000	\$ 10
	=====	=====	=====

The non-cash expenditures presented as reductions of the asset write-down restructuring charge represent disposals of fully written-down assets, including rationalized inventories and impairments to long-lived assets held for disposal consisting of machinery, equipment and computer software.

Restructuring costs incurred but not yet paid have been credited to accrued expense and asset write-downs have been credited against the applicable asset accounts. Substantially all of the remaining restructuring accruals as of March 31, 2002 are expected to be paid out during fiscal year 2002.

NOTE E - COMPREHENSIVE INCOME

The components of comprehensive income, net of tax, were as follows:

	Three Months Ended	
	March 31, 2002	March 31, 2001
	-----	-----
Net income	\$ 11,316,000	\$ 9,313,000
Foreign currency translation (losses) gains	(135,000)	(599,000)
	-----	-----
Comprehensive income	\$ 11,181,000	\$ 8,714,000
	=====	=====

NOTE F - ACQUISITION

On April 12, 2002, the Company completed its previously announced acquisition of Novamatrix Medical Systems Inc. ("Novamatrix"), a leading cardiorespiratory monitoring company that develops, manufactures, and markets proprietary state-of-the-art noninvasive monitors, sensors, and disposable accessories. The acquisition of Novamatrix was consummated pursuant to an Agreement and Plan of Merger dated as of December 17, 2001, pursuant to which Respiroics Holdings, Inc., a wholly owned subsidiary of the Company, was merged with and into Novamatrix (the "Merger"). The Company made this acquisition because the Novamatrix monitoring products complement the Company's therapeutic products used in the hospital environment, the Novamatrix developmental care products complement the Company's infant management products and programs, the Novamatrix cardiac output monitoring technologies support the Company's initiatives in the congestive heart failure area, and with the acquisition, the Company's "critical mass" of products, revenues, profits, and assets in these markets increased. The results of operations of Novamatrix are not included in the Company's consolidated income statements for the period ended March 31, 2002 because the acquisition was completed after that date.



## Edgar Filing: RESPIRONICS INC - Form 10-Q

Upon consummation of the Merger, approximately 2,400,000 shares of the Company's common stock were issued to the former stockholders of Novamatrix, reflecting an exchange ratio of .2541 shares of the Company's common stock for each share of Novamatrix common stock. The exchange ratio was determined based on the weighted average selling price of \$31.48 for the Company's common stock for the 20 day trading period from March 11 through April 8, 2002. Novamatrix stockholders received the Company's stock in an amount equal to \$8.00 per Novamatrix share based upon the weighted average selling price. In addition, approximately 509,000 shares of the Company's common stock were reserved for issuance upon exercise of options and warrants issued in replacement of Novamatrix options and warrants that were not exercised prior to the consummation of the Merger. As of the close of trading on April 12, 2002, Novamatrix common stock ceased to be traded on the Nasdaq National Market.

The total value of the Company's shares issued and reserved for issuance in the transaction was approximately \$81 million based on the market price of the Company's common stock issued and reserved for issuance.

The following table summarizes the preliminary estimated fair value of the assets acquired and liabilities assumed at the date of acquisition. Because the acquisition closed subsequent to the end of the most recent quarter, the Company is in the very early stages of the purchase price allocation and is in the process of obtaining third party valuations of certain intangible assets; therefore the allocation of the purchase price is subject to refinement.

At April 12, 2002

Current assets, primarily consisting of accounts receivable and inventories	\$28,400,000
Property, plant and equipment	3,000,000
Other assets, including intangible assets	31,300,000
Goodwill	33,700,000
	-----
Total assets acquired	\$96,400,000
Current liabilities, primarily consisting of accounts payable, accrued expenses, and current portion of debt	\$ 14,000,000
Long term debt	1,400,000
	-----
Total liabilities assumed	\$ 15,400,000
Net Assets Acquired	\$ 81,000,000

The amounts assigned to major classes of intangible assets, related amortization periods, and determinations regarding the tax deductibility of such amortization have not been completed.

The pro forma summary below presents the Company's results of operations as if the acquisition had occurred at the beginning of the periods presented and does not purport to be indicative of what would have occurred had the acquisitions been made as of those dates or of results which may occur in the future. These results do not include the positive impact of cost reductions and other synergies that are expected to be realized as a result of the acquisition.

Edgar Filing: RESPIRONICS INC - Form 10-Q

	Nine months ended March 31	
	2002	2001
	-----	-----
Pro Forma Sales	\$388,793,000	\$347,048,000
Pro Forma Net Income	31,237,000	24,887,000
Pro Forma Earnings Per Share	0.93	0.75

Novamatrix had an April fiscal year end, which differed from the Company's June year end, and accordingly the companies' fiscal quarters also end on different dates. In order to develop the pro forma information above, the Company's unaudited income statements for the nine-month periods ended March 31, 2002 and 2001 were combined with Novamatrix's unaudited income statements for the nine-month periods ended January 31, 2002 and 2001. Earnings per share data are based on the Company's weighted average number of common shares outstanding plus the total number of the Company's common shares and equivalents delivered to Novamatrix stockholders as part of the acquisition.

NOTE G - RECENT ACCOUNTING PRONOUNCEMENTS

In June 2001, the Financial Accounting Standards Board issued Statements of Financial Accounting Standards No. 141, "Business Combinations," ("FAS 141") and No. 142, "Goodwill and Other Intangible Assets," ("FAS 142") effective for fiscal years beginning after December 15, 2001. Under the new rules, goodwill and intangible assets deemed to have indefinite lives will no longer be amortized but will be subject to annual impairment tests in accordance with the Statements. Other intangible assets will continue to be amortized over their useful lives. The Company will apply the provisions of FAS 141 to account for any business combination that is consummated after July 1, 2001, including the acquisition of Novamatrix described in Note F.

The Company will apply the new rules under FAS 142 on accounting for goodwill and other intangible assets beginning in the first quarter of fiscal year 2003. Application of the nonamortization provisions of the Statement is expected to result in an increase in annual net income of approximately \$3,000,000 or \$0.08 per diluted share. During fiscal year 2003, the Company will perform the first of the required impairment tests of goodwill and indefinite lived intangible assets as of July 1, 2002.

CAUTIONARY STATEMENT FOR PURPOSES OF THE "SAFE HARBOR" PROVISIONS OF THE PRIVATE SECURITIES REFORM ACT OF 1995.

The statements contained in this Quarterly Report on Form 10-Q, specifically those contained in Item 2 "Management's Discussion and Analysis of Financial Condition and Results of Operations", along with statements in other sections of this document and other reports filed with the Securities and Exchange Commission, external documents and oral presentations which are not historical are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21B of the Securities and Exchange Act of 1934, as amended. These forward-looking statements represent the Company's present expectations or beliefs concerning future events. The Company cautions that such statements are qualified by important factors that

## Edgar Filing: RESPIRONICS INC - Form 10-Q

could cause actual results to differ materially from those in the forward-looking statements. Results actually achieved may differ materially from expected results included in these statements. Those factors include, but are not limited to, the following: foreign currency fluctuations, regulations and other factors affecting operations and sales outside the United States including potential future effects of the change in sovereignty of Hong Kong, customer consolidation and concentration, increasing price competition and other competitive factors in the sale of products, the success of programs, interest rate fluctuations, intellectual property and related litigation, other litigation, successful integration of acquisitions, FDA and other government regulation, anticipated levels of earnings and revenues, and third party reimbursement.

### Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

#### RESULTS OF OPERATIONS

Net sales for the three months ended March 31, 2002 were \$126,708,000 representing a 15% increase over the sales of \$110,208,000 recorded for the three months ended March 31, 2001. Increases in unit and dollar sales for the Company's sleep apnea therapy devices (the Company's largest product line) and oxygen concentrator devices, as well as increases in the sales of masks and accessories, helped to drive the increase in sales for the quarter. Sales of the Company's non-invasive ventilation devices (units used to assist patients suffering from breathing disorders via airflow delivered through a mask) also increased during the quarter, particularly sales of the Company's BiPAP(R) Synchrony(TM) Ventilatory Support System, which was introduced during fiscal year 2001. These product lines comprise the major part of the Company's homecare product offerings. Sales of the Company's hospital products also increased during the current quarter, particularly sales of the Company's BiPAP(R) Vision(TM) ventilator.

Net sales for the nine months ended March 31, 2002 were \$351,501,000 representing a 15% increase over the sales of \$306,820,000 recorded for the nine months ended March 31, 2001. Increases in the Company's sleep apnea therapy devices, oxygen concentrators, and masks and accessories as discussed above accounted for the majority of the increase in sales, along with increased sales of the Company's BiPAP(R) Synchrony(TM) non-invasive ventilation device and the Company's hospital BiPAP(R) Vision(TM) ventilator.

The Company's gross profit was 47% of net sales for the quarters and nine months ended March 31, 2002 and 2001, excluding the impact of restructuring charges in the prior year. This static gross profit percentage reflects the impact of higher revenue levels, offset by the impact of sales mix and selling price decreases consistent with those decreases seen in prior years.

General and administrative expenses were \$15,398,000 (12% of net sales) for the quarter ended March 31, 2002 as compared to \$13,222,000 (12% of net sales) for the quarter ended March 31, 2001. For the nine-month period ended March 31, 2002, general and administrative expenses were \$42,452,000 (12% of net sales) as compared to \$37,052,000 (12% of net sales) for the prior year nine-month period. The increases in absolute dollars of general and administrative expenses for the current quarter and nine-month periods were due primarily to increases in spending consistent with the growth of the Company's business. The prior-year periods also included an addition to the allowance for doubtful accounts of \$1,200,000 related to one of the Company's significant hospital distribution customers ceasing operations.

Sales, marketing and commission expenses were \$21,119,000 (17% of net sales) for the quarter ended March 31, 2002 as compared to

## Edgar Filing: RESPIRONICS INC - Form 10-Q

\$18,640,000 (17% of net sales) for the quarter ended March 31, 2001. For the nine-month period ended March 31, 2002, sales, marketing and commission expenses were \$60,175,000 (17% of net sales) as compared to \$53,059,000 (17% of net sales) for the prior year nine-month period. The increases in absolute dollars of expense for the current quarter and nine-month periods were due primarily to increased sales (resulting in higher commission and sales bonus expenses) and increased sales, marketing, product support, and service activity levels across the Company's product lines during the current year.

Research and development expenses were \$3,904,000 (3% of net sales) for the quarter ended March 31, 2002 as compared to \$3,745,000 (3% of net sales) for the quarter ended March 31, 2001. For the nine-month period ended March 31, 2002, research and development expenses were \$12,206,000 (3% of net sales) as compared to \$10,843,000 (4% of net sales) for the prior year nine-month period. The increases in absolute dollars of expense for the current quarter and nine-month periods were due to the Company's continuing commitment to research, development and new product introductions. During the current quarter the Company introduced several new products including a continuous positive airway pressure ("CPAP") sleep therapy unit called the REMstar(R) Auto, the H2 Heated Humidifier, the latest addition to the Company's line of heated humidifiers for CPAP and bi-level devices, and the new ComfortSelect(TM) Nasal Mask. Significant product development efforts are ongoing and new product launches in many of the Company's major product lines are scheduled for the next twelve to eighteen months. Additional development work and clinical trials are being conducted in certain product areas outside the Company's current core products, including congestive heart failure.

During the three months ended March 31, 2001, the Company incurred restructuring charges of \$800,000, related to a previously disclosed restructuring. These costs were primarily for asset write-downs to reflect decisions made regarding product, facility, and systems rationalization and other direct expenses of the restructuring. Approximately \$700,000 of these charges related to inventory write-offs of discontinued products and have been reported as a separate component of cost of goods sold. Also as part of the restructuring, during the three months ended March 31, 2001, the Company's Westminster, Colorado facility was sold and a gain of approximately \$2,000,000 was recorded on the sale. There were no restructuring costs during the three-month and nine-month periods ended March 31, 2002.

The Company's effective income tax rate was approximately 40% for all periods presented.

As a result of the factors described above, the Company's net income was \$11,316,000 (9% of net sales) or \$0.36 per diluted share for the quarter ended March 31, 2002 as compared to net income of \$9,313,000 (8% of net sales) or \$0.30 per diluted share for the quarter ended March 31, 2001. For the nine-month period ended March 31, 2002, the Company's net income was \$29,375,000 (8% of net sales) or \$0.94 per diluted share as compared to net income of

\$23,614,000 (8% of net sales) or \$0.77 per diluted share for the prior year nine-month period.

### FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES

The Company had working capital of \$191,144,000 at March 31, 2002 and \$171,985,000 at June 30, 2001. Net cash provided by operating activities was \$55,841,000 for the nine months ended March 31, 2002 as compared to \$26,141,000 for the nine months ended March 31, 2001. The increase in cash provided by operating activities for the current nine-month period was primarily due to

## Edgar Filing: RESPIRONICS INC - Form 10-Q

higher earnings, reductions in inventory, and the positive impact of changes in other operating assets and liabilities.

Net cash used by investing activities was \$23,547,000 for the nine months ended March 31, 2002 as compared to \$23,438,000 for the nine months ended March 31, 2001. Cash used by investing activities for both periods include capital expenditures, including the purchase of leasehold improvements, production equipment, computer hardware and software, and telecommunications and office equipment. In addition, cash used by investing activities in the periods described includes additional purchase price paid for a previously acquired business pursuant to the terms of that acquisition agreement. The funding for investment activities in both periods was provided by positive cash flow from operating activities and accumulated cash and short-term investments.

Net cash used or provided by financing activities consists primarily of repayments under the Company's various long-term obligations and proceeds from the issuance of common stock under the Company's stock option plans. Net cash used by financing activities was \$10,787,000 for the nine months ended March 31, 2002 as compared to \$7,883,000 for the nine months ended March 31, 2001. Included in net cash used by financing activities were net debt paydowns of \$14,015,000 and \$15,218,000 for the nine-month periods ended March 31, 2002 and 2001, respectively. The increase in cash used by financing activities was due primarily to a reduction in proceeds from the issuance of stock under the Company's stock option plans compared to prior year amounts.

The Company has contractual financial obligations and commercial financial commitments consisting primarily of long-term debt, capital lease obligations, and non-cancelable operating leases. The composition and nature of these obligations and commitments have not changed materially since June 30, 2001. See the Notes to the Company's Consolidated Financial Statements in its Annual Report on Form 10-K for the year ended June 30, 2001 for information about these obligations and commitments.

The following table summarizes significant contractual obligations and commercial commitments of the Company as of March 31, 2002:

### Contractual Obligations and Commercial Commitments

	Payments Due by Period		
Contractual Obligations	Total	Less Than 1 Year	1-3 Years
Long-Term Debt	\$ 69,854,973	\$ 478,453	\$69,095,353
Capital Lease Obligations	183,470	183,470	--
Operating Leases	24,915,998	4,714,321	10,749,994
Total Contractual Obligations	\$ 94,954,441	\$ 5,376,244	\$79,845,347

Amount of Commitment E

Edgar Filing: RESPIRONICS INC - Form 10-Q

Other Commercial Commitments	Total Amounts Committed	Less Than 1 Year	1-3 Years
Standby Letters of Credit	\$ 2,024,000	\$ 2,024,000	\$ --

In connection with customer leasing programs with independent leasing companies, the Company is contingently liable, in the event of a customer default, to the leasing companies for certain unpaid installment receivables transferred to the leasing companies. The total exposure for unpaid installment receivables was approximately \$18,953,000 at March 31, 2002 as compared to \$22,670,000 at June 30, 2001. The transfer of these installment receivables meets the criteria of Statement of Financial Accounting Standards No. 125, "Accounting for Transfers and Servicing of Financial Assets and Extinguishment of Liabilities," (and Statement of Financial Accounting Standards No. 140, "Accounting for Transfers and Servicing of Financial Assets and Extinguishment of Liabilities," which was effective for such transfers that occurred after March 31, 2001) and therefore, these receivables are not recorded on the Company's financial statements.

The Company's revolving credit agreement expires April 30, 2003. The Company has begun discussions with several commercial banks including certain of the banks participating in the Company's current credit facility regarding renewing or replacing the Company's existing revolving credit agreement. The Company expects to have a new credit agreement in place prior to the expiration of the existing credit agreement. The amount that would be available for borrowing under the new credit agreement has not yet been determined, but is currently expected to be at least \$125,000,000, the amount of the current revolver.

The Company believes that its sources of funding (consisting of projected positive cash flow from operating activities, the availability of additional funds under its revolving credit facility (totaling approximately \$55,076,000 at March 31, 2002), and its accumulated cash and short-term investments) will be sufficient to meet its current and presently anticipated short-term and long-term future needs for operating activities (including payments against restructuring accruals), investing activities, and financing activities (primarily consisting of scheduled payments on long-term debt).

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

The Company is exposed to market risk from changes in interest rates and foreign exchange rates.

**Interest Rates:** The Company's primary interest rate risk relates to its long-term debt obligations. At March 31, 2002, the Company had total long-term debt obligations, including the current portion of those obligations, of \$70,039,000. Of that amount, \$1,539,000 was in fixed rate obligations and \$68,500,000 was in variable rate obligations. Assuming a 10% increase in interest rates on the Company's variable rate obligations (i.e. an increase from the March 31, 2002 weighted average interest rate of 2.44% to a weighted average interest rate of 2.68%), annual interest expense

would be approximately \$167,000 higher based on the March 31, 2002 outstanding balance of variable rate obligations. The Company has no interest rate swap or exchange agreements.

**Foreign Exchange Rates:** Information relating to the sensitivity to foreign

## Edgar Filing: RESPIRONICS INC - Form 10-Q

currency exchange rate changes is omitted because foreign exchange exposure risk has not materially changed from that disclosed in the Company's Annual Report on Form 10-K for the year ended June 30, 2001.

### Inflation

Inflation has not had a significant effect on the Company's business during the periods discussed.

### Recent Accounting Pronouncements

In June 2001, the Financial Accounting Standards Board issued Statements of Financial Accounting Standards No. 141, "Business Combinations," ("FAS 141") and No. 142, "Goodwill and Other Intangible Assets," ("FAS 142") effective for fiscal years beginning after December 15, 2001. Under the new rules, goodwill and intangible assets deemed to have indefinite lives will no longer be amortized but will be subject to annual impairment tests in accordance with the Statements. Other intangible assets will continue to be amortized over their useful lives. The Company will apply the provisions of FAS 141 to account for any business combination that is consummated after July 1, 2001, including the acquisition of Novamatrix described in Note F.

The Company will apply the new rules under FAS 142 on accounting for goodwill and other intangible assets beginning in the first quarter of fiscal year 2003. Application of the nonamortization provisions of the Statement is expected to result in an increase in annual net income of approximately \$3,000,000 or \$0.08 per diluted share. During fiscal year 2003, the Company will perform the first of the required impairment tests of goodwill and indefinite lived intangible assets as of July 1, 2002.

In August 2001, Statement of Financial Accounting Standards No. 143 ("FAS 143"), "Accounting for Asset Retirement Obligations," was issued. This Statement requires recording the fair value of a liability for an asset retirement obligation in the period in which it is incurred, and a corresponding increase in the carrying value of the related long-lived asset. Over time, the liability is accreted to its present value each period, and the capitalized cost is depreciated over the useful life of the related asset. Upon settlement of the liability, it is either settled for its recorded amount or a gain or loss upon settlement is recorded. FAS 143 is effective for the Company's fiscal year ended June 30, 2003. The

Company is currently assessing, but has not yet determined, the impact of FAS 143 on its financial position and results of operations.

In August 2001, Statement of Financial Accounting Standards No. 144 ("FAS 144"), "Accounting for the Impairment or Disposal of Long-Lived Assets," was issued. This Statement addresses financial accounting and reporting for the impairment or disposal of long-lived assets. This Statement supercedes FAS Statement No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of," and the accounting and reporting provisions of Accounting Principles Board ("APB") Opinion No. 30, "Reporting the Results of Operations - Reporting the Effects of Disposal of a Segment of a Business, and Extraordinary, Unusual and Infrequently Occurring Events and Transactions," for the disposal of a segment of a business (as previously defined in that Opinion). FAS 144 is effective for the Company's fiscal year ended June 30, 2003. The Company is currently assessing, but has not yet determined, the impact of FAS 144 on its financial position and results of operations.

Edgar Filing: RESPIRONICS INC - Form 10-Q

PART 2 OTHER INFORMATION

Item 1: Legal Proceedings  
-----

The Company is, as a normal part of its business operations, a party to other legal proceedings in addition to those previously described by filings of the Company. Legal counsel has been retained for each proceeding and none of these proceedings is expected to have a material adverse impact on the Company's results of operations or financial condition.

Item 2: Changes in Securities  
-----

- (a) Not applicable
- (b) Not applicable
- (c) Not applicable

Item 3: Defaults Upon Senior Securities  
-----

- (a) Not applicable
- (b) Not applicable

Item 4: Submission of Matters to a Vote of Security Holders  
-----

Not applicable.

Item 5: Other Information  
-----

Effective May 13, 2002, the address of the Company's principal executive offices has changed to 1010 Murry Ridge Lane, Murrysville, Pennsylvania 15668-8525, and the Company's telephone number is now 724-387-5200.

Item 6: Exhibits and Reports on Form 8-K  
-----

- (a) Exhibits  
  
Exhibit 15 Acknowledgement of Ernst & Young LLP.
- (b) Reports on Form 8-K  
  
None.

SIGNATURES  
-----

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

RESPIRONICS, INC.

Date: May 15, 2002

/s/ Daniel J. Bevevino



Edgar Filing: RESPIRONICS INC - Form 10-Q

-----  
-----  
Daniel J. Bevevino  
Vice President, and Chief  
Financial and Principal  
Accounting Officer

Signing on behalf of the  
registrant and as Chief  
Financial and Principal  
Accounting Officer